<DOC>
	<DOCNO>NCT03033849</DOCNO>
	<brief_summary>The user performance evaluation show whether people diabetes able obtain accurate measurement result blood glucose monitoring system . In study , user performance evaluation perform Contour® Next One ( Ascensia Diabetes Care GmbH ) , Accu-Chek® Aviva Connect ( Roche Diabetes Care GmbH ) , FreeStyle Freedom Lite ( Abbott Diabetes Care Inc. ) , OneTouch® Verio ( LifeScan Europe ) GlucoMen® areo A. Menarini Diagnostics S.r.l . ( base ISO 15197:2013 ; EN ISO 15197:2015 , clause 8 . For BGMS , measurement procedure user performance evaluation perform 1 test meter 1 reagent system lot study subject . The meter additional test meter use double measurement perform study personnel ( reagent system lot use subject ) .</brief_summary>
	<brief_title>User Performance Evaluation Contour® Next One , Accu-Chek® Aviva Connect , FreeStyle Freedom Lite , OneTouch® Verio GlucoMen® Areo Blood Glucose Monitoring Systems Following ISO 15197:2013</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Male female , type 1 diabetes , type 2 diabetes subject without diabetes Signed informed consent form Minimum age 18 year Subjects legally competent capable understand character , mean consequence study . If blood glucose value &lt; 80 mg/dl &gt; 300 mg/dl shall measure short term alteration insulin therapy : Male female type 1 diabetes intensified insulin therapy insulin pump therapy . Signature subject document consent procedure inform consent form . Pregnancy lactation period Severe acute disease ( study physician 's discretion ) Severe chronic disease potential risk test procedure ( study physician 's discretion ) Current constitution compromise subject 's capability participate study ( study physician 's discretion ) Being unable give inform consent &lt; 18 year Legally incompetent Being commit institution ( e.g . psychiatric clinic ) Language barrier potentially compromise adequate compliance study procedure Dependent investigator sponsor If blood glucose value &lt; 80 mg/dl shall measure short term alteration insulin therapy , subject type 1 diabetes , suffering : Coronary heart disease Condition myocardial infarction Condition cerebral event Peripheral arterial occlusive disease Hypoglycemia unawareness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>